Can Prolia Cause Vision Changes?
Vision changes are not a commonly reported adverse effect of Prolia (denosumab), though rare ocular complications have been documented in case reports and comparative studies.
Evidence from Clinical Trials and Guidelines
The major clinical trials and guidelines for denosumab do not identify vision changes as a significant adverse effect. In the large ABCSG-18 trial (n=3,420 patients), the most common serious adverse events were osteoarthritis, meniscus injury, and cataract (0.9% in denosumab group vs 1.7% in placebo group) 1. Notably, cataracts occurred less frequently with denosumab than placebo in this study. The D-CARE trial (n=4,509 patients) similarly did not report vision changes as a notable adverse event 1.
The American College of Physicians guideline on osteoporosis treatment lists uveitis or ocular events as potential adverse effects specifically associated with zoledronic acid (a bisphosphonate), but does not mention ocular complications with denosumab 2. The guideline notes only mild upper GI symptoms and rash/eczema as denosumab-specific adverse effects 2.
Rare Ocular Complications: What to Watch For
While not common, specific vision-related complications have been reported:
Band Keratopathy
A case report documented band keratopathy (calcific deposits in the cornea) developing in a 75-year-old woman after denosumab therapy, causing progressive vision loss 3. This occurred because denosumab influences calcium metabolism, potentially leading to abnormal calcium deposition in the cornea. The condition required surgical treatment with keratectomy 3.
Cataract Risk
A large comparative study of 118,292 patients found that denosumab was actually associated with a modestly decreased risk of cataract surgery compared to zoledronic acid (HR 0.91; 95% CI 0.85-0.98) 4. The risk of age-related macular degeneration was similar between the two drugs 4.
Clinical Approach
If a patient on Prolia reports vision changes:
- Consider band keratopathy if symptoms include progressive vision loss, particularly if there are visible corneal changes on examination
- Evaluate for hypercalcemia or abnormal calcium metabolism through laboratory workup
- Refer to ophthalmology for comprehensive evaluation
- The temporal association between denosumab initiation and vision symptoms is important to establish
Common pitfalls to avoid:
- Do not dismiss vision complaints in patients on denosumab, even though they are rare
- Remember that denosumab affects calcium metabolism systemically, which can theoretically impact ocular tissues
- Band keratopathy may require discontinuation of denosumab and specific ophthalmologic intervention
Bottom Line
Vision changes are not a standard adverse effect of Prolia based on large clinical trials and guidelines. However, rare cases of band keratopathy have been reported 3, and any new vision symptoms warrant ophthalmologic evaluation to rule out calcium-related corneal deposits or other ocular pathology.